ǸԹ

Skip to main content
Research and analysis

Shingles immunisation programme [Shingrix®]: evaluation reports

Evaluation of the Shingrix® herpes zoster (shingles) vaccination programme in England: academic years 2023/24, and 2024/25.

Applies to England

Documents

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

For reports covering earlier years, when Zostavax® was in use, see Herpes zoster (shingles) immunisation programme 2023/24: evaluation reports.

Updates to this page

Published 29 August 2024
Last updated 1 May 2026 show all updates
  1. Annual report for 2024/25 (with suffix "updated version 2") substituted fror original version. (Version 2 includes data from both GP IT suppliers; first version took account of data from only 57.9% of GPs.)

  2. Added latest quarterly report and associated data file.

  3. Added data file associated with the annual report for 2024/25.

  4. Added annual report for academic year 2024/25.

  5. Added the HPR 19(10) report, the third quarterly report for the academic year 2024/25, and the associated data file.

  6. Added the HPR 19(7) report, the second quarterly report for the academic year 2024/25, and the associated data file.

  7. Added the HPR 19(4) report, the first quarterly report for the academic year 2024/2025, and the associated data file.

  8. Added quarterly report for Q3 of epidemiological year 2023/24.

  9. Added quarterly report and data file for Q2 of epidemiological year 2023/24.

  10. First published.

Sign up for emails or print this page